Astrana Health (NASDAQ:ASTH – Get Free Report) and Bioqual (OTCMKTS:BIOQ – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.
Volatility & Risk
Astrana Health has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500.
Earnings and Valuation
This table compares Astrana Health and Bioqual”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Astrana Health | $2.03 billion | 0.81 | $43.15 million | $0.51 | 57.49 |
| Bioqual | $48.87 million | 0.73 | -$1.05 million | ($1.18) | -33.90 |
Astrana Health has higher revenue and earnings than Bioqual. Bioqual is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Astrana Health and Bioqual’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Astrana Health | 1.04% | 3.43% | 1.87% |
| Bioqual | -2.14% | -2.90% | -1.87% |
Institutional and Insider Ownership
52.8% of Astrana Health shares are held by institutional investors. 8.5% of Astrana Health shares are held by insiders. Comparatively, 39.2% of Bioqual shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations for Astrana Health and Bioqual, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Astrana Health | 1 | 3 | 4 | 0 | 2.38 |
| Bioqual | 0 | 0 | 0 | 0 | 0.00 |
Astrana Health currently has a consensus price target of $47.40, suggesting a potential upside of 61.66%. Given Astrana Health’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Astrana Health is more favorable than Bioqual.
Summary
Astrana Health beats Bioqual on 13 of the 14 factors compared between the two stocks.
About Astrana Health
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.
About Bioqual
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
